Perimenopause and risk of psychiatric disorders: a longitudinal, population-based study
围绝经期和精神疾病的风险:一项基于人群的纵向研究
基本信息
- 批准号:MR/W004658/1
- 负责人:
- 金额:$ 55.39万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2022
- 资助国家:英国
- 起止时间:2022 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
THE PROBLEMThere are over 1.2 billion women over the age of 45 in the world, 29 million in the UK. About 70% of them develop neurological and psychiatric symptoms during perimenopause (the years around the final menstrual period). It has been suggested that perimenopause is also a high-risk period for the onset or exacerbation of psychiatric disorders, including major depression, schizophrenia and bipolar disorder. Research thus far has mainly focused on depressive symptoms. The very few studies that have investigated clinically significant major depression have found a 2-4 times greater risk of becoming unwell during perimenopause compared to the pre-menopause, even after controlling for other symptoms and predictors. Professional bodies and institutions worldwide have highlighted the gender gap in mental health, including the knowledge gap on the effects of reproductive ageing. Little and inconsistent information is available on severe mental disorders and, more broadly, on the factors that may predispose women to become unwell during the transition to menopause. This lack of information is a major issue for women, their families and carers. Some women who develop psychiatric disorders during perimenopause may not have any psychiatric history or may have been well for many years and not in contact with psychiatric services. Identifying these women and providing them with the necessary care is of vital importance. THE RESEARCHThis research will address the current lack of information on the risk of severe mental illness related to perimenopause. It will systematically investigate a population of over 160,000 middle-aged UK women who have been followed up to the postmenopause using interviews and electronic health records from primary care and hospital admission. Data will be extracted and cleaned using standard procedures. We will calculate the risk of mental disorders at different time periods. We will test the hypothesis that the late perimenopause is a period of increased risk of mental disorders. As not all women are the same, we will seek to identify groups of women with similar risk profiles. We will also explore the effect of psycho-social, clinical and genetic factors on the risk of becoming unwell. Women with lived experience have been involved in the design of this study and will be involved at all stages of research to provide input via an advisory group. They will also give talks at workshops and dissemination events. BENEFITS The findings of this study will help identify women at risk of developing mental illness in relation to the perimenopause. These women may benefit from closer monitoring and will be empowered to take steps to manage their own health to avoid relapse. Prompt recognition of early signs of illness will allow more rapid treatment, with the potential to save lives.By providing evidence-based, easy-to-understand information to the public, the research may also contribute to raising awareness of the risks of mental illness during perimenopause. Moreover, it has the potential to give women themselves the tools to manage their illness more effectively and to contribute to the de-stigmatization of mental disorders associated to the perimenopause.The results will also have the potential to improve the current approach to diagnosis, prevention and treatment of psychiatric disorders in middle-aged women by influencing guidelines and informing risk assessment tools.The long-term goal is to improve personalised risk predictions and ultimately how we help women with perimenopause mental disorder, reducing the impact of episodes of illness in women at risk. Given the association between poor mental health in middle-age years and general health outcomes, our research also has the potential to contribute to improving the general health and wellbeing of women.
问题:全世界45岁以上的女性超过12亿,其中英国有2900万。其中约70%的人在围绝经期(最后一次月经前后的几年)出现神经和精神症状。有研究表明,围绝经期也是精神疾病发病或加重的高危期,包括重度抑郁症、精神分裂症和双相情感障碍。迄今为止的研究主要集中在抑郁症状上。很少有研究发现,即使在控制了其他症状和预测因素之后,围绝经期出现身体不适的风险是绝经前的2-4倍。世界各地的专业团体和机构都强调了心理健康方面的性别差距,包括关于生殖老龄化影响的知识差距。关于严重精神障碍的资料很少,也不一致,更广泛地说,关于妇女在过渡到更年期期间易患病的因素的资料也很少。对妇女、她们的家庭和照顾者来说,缺乏信息是一个重大问题。一些在围绝经期出现精神疾病的妇女可能没有任何精神病史,或者可能多年来一直很好,但没有接触过精神科服务。确定这些妇女并为她们提供必要的护理至关重要。研究:这项研究将解决目前缺乏与围绝经期有关的严重精神疾病风险的信息。它将系统地调查超过16万名中年英国妇女的人口,这些妇女通过访谈和初级保健和住院的电子健康记录被跟踪到绝经后。使用标准程序提取和清理数据。我们将计算不同时期精神障碍的风险。我们将检验这一假设,即绝经后期是精神障碍风险增加的时期。由于并非所有妇女都是一样的,我们将设法确定具有类似风险概况的妇女群体。我们还将探讨心理社会、临床和遗传因素对患病风险的影响。有实际经验的妇女参与了这项研究的设计,并将参与研究的所有阶段,通过一个咨询小组提供投入。他们还将在讲习班和宣传活动上发表演讲。益处:这项研究的发现将有助于确定女性是否有患与绝经期有关的精神疾病的风险。这些妇女可能受益于更密切的监测,并将有权采取措施管理自己的健康,以避免复发。及时识别疾病的早期迹象将有助于更迅速地进行治疗,从而有可能挽救生命。通过向公众提供基于证据的、易于理解的信息,这项研究也可能有助于提高人们对围绝经期精神疾病风险的认识。此外,它有可能为妇女本身提供更有效地管理疾病的工具,并有助于消除对与绝经期有关的精神障碍的污名化。研究结果还将有可能通过影响指导方针和为风险评估工具提供信息,改进目前对中年妇女精神疾病的诊断、预防和治疗方法。长期目标是改善个性化的风险预测,并最终帮助患有围绝经期精神障碍的女性,减少疾病发作对处于危险中的女性的影响。鉴于中年心理健康状况不佳与总体健康状况之间的关联,我们的研究也有可能有助于改善女性的总体健康和福祉。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arianna Di Florio其他文献
75. GWAS IDENTIFIES NOVEL LOCI ASSOCIATED WITH SPECIFIERS OF BIPOLAR DISORDER
全基因组关联研究确定了与双相情感障碍特征相关的新位点
- DOI:
10.1016/j.euroneuro.2024.08.189 - 发表时间:
2024-10-01 - 期刊:
- 影响因子:6.700
- 作者:
Shane Crinion;Tracey van der Veen;Markos Tesfaye;Arianna Di Florio;Andrew McQuillin;Niamh Mullins;Psychiatric Genomics Consortium Bipolar Disorder Working Group Psychiatric Genomics Consortium Bipolar Disorder Working Group - 通讯作者:
Psychiatric Genomics Consortium Bipolar Disorder Working Group Psychiatric Genomics Consortium Bipolar Disorder Working Group
Genomics yields biological and phenotypic insights into bipolar disorder
基因组学对双相情感障碍产生了生物学和表型方面的见解
- DOI:
10.1038/s41586-024-08468-9 - 发表时间:
2025-01-22 - 期刊:
- 影响因子:48.500
- 作者:
Kevin S. O’Connell;Maria Koromina;Tracey van der Veen;Toni Boltz;Friederike S. David;Jessica Mei Kay Yang;Keng-Han Lin;Xin Wang;Jonathan R. I. Coleman;Brittany L. Mitchell;Caroline C. McGrouther;Aaditya V. Rangan;Penelope A. Lind;Elise Koch;Arvid Harder;Nadine Parker;Jaroslav Bendl;Kristina Adorjan;Esben Agerbo;Diego Albani;Silvia Alemany;Ney Alliey-Rodriguez;Thomas D. Als;Till F. M. Andlauer;Anastasia Antoniou;Helga Ask;Nicholas Bass;Michael Bauer;Eva C. Beins;Tim B. Bigdeli;Carsten Bøcker Pedersen;Marco P. Boks;Sigrid Børte;Rosa Bosch;Murielle Brum;Ben M. Brumpton;Nathalie Brunkhorst-Kanaan;Monika Budde;Jonas Bybjerg-Grauholm;William Byerley;Judit Cabana-Domínguez;Murray J. Cairns;Bernardo Carpiniello;Miquel Casas;Pablo Cervantes;Chris Chatzinakos;Hsi-Chung Chen;Tereza Clarence;Toni-Kim Clarke;Isabelle Claus;Brandon Coombes;Elizabeth C. Corfield;Cristiana Cruceanu;Alfredo Cuellar-Barboza;Piotr M. Czerski;Konstantinos Dafnas;Anders M. Dale;Nina Dalkner;Franziska Degenhardt;J. Raymond DePaulo;Srdjan Djurovic;Ole Kristian Drange;Valentina Escott-Price;Ayman H. Fanous;Frederike T. Fellendorf;I. Nicol Ferrier;Liz Forty;Josef Frank;Oleksandr Frei;Nelson B. Freimer;John F. Fullard;Julie Garnham;Ian R. Gizer;Scott D. Gordon;Katherine Gordon-Smith;Tiffany A. Greenwood;Jakob Grove;José Guzman-Parra;Tae Hyon Ha;Tim Hahn;Magnus Haraldsson;Martin Hautzinger;Alexandra Havdahl;Urs Heilbronner;Dennis Hellgren;Stefan Herms;Ian B. Hickie;Per Hoffmann;Peter A. Holmans;Ming-Chyi Huang;Masashi Ikeda;Stéphane Jamain;Jessica S. Johnson;Lina Jonsson;Janos L. Kalman;Yoichiro Kamatani;James L. Kennedy;Euitae Kim;Jaeyoung Kim;Sarah Kittel-Schneider;James A. Knowles;Manolis Kogevinas;Thorsten M. Kranz;Kristi Krebs;Steven A. Kushner;Catharina Lavebratt;Jacob Lawrence;Markus Leber;Heon-Jeong Lee;Calwing Liao;Susanne Lucae;Martin Lundberg;Donald J. MacIntyre;Wolfgang Maier;Adam X. Maihofer;Dolores Malaspina;Mirko Manchia;Eirini Maratou;Lina Martinsson;Manuel Mattheisen;Nathaniel W. McGregor;Melvin G. McInnis;James D. McKay;Helena Medeiros;Andreas Meyer-Lindenberg;Vincent Millischer;Derek W. Morris;Paraskevi Moutsatsou;Thomas W. Mühleisen;Claire O’Donovan;Catherine M. Olsen;Georgia Panagiotaropoulou;Sergi Papiol;Antonio F. Pardiñas;Hye Youn Park;Amy Perry;Andrea Pfennig;Claudia Pisanu;James B. Potash;Digby Quested;Mark H. Rapaport;Eline J. Regeer;John P. Rice;Margarita Rivera;Eva C. Schulte;Fanny Senner;Alexey Shadrin;Paul D. Shilling;Engilbert Sigurdsson;Lisa Sindermann;Lea Sirignano;Dan Siskind;Claire Slaney;Laura G. Sloofman;Olav B. Smeland;Daniel J. Smith;Janet L. Sobell;Maria Soler Artigas;Dan J. Stein;Frederike Stein;Mei-Hsin Su;Heejong Sung;Beata Świątkowska;Chikashi Terao;Markos Tesfaye;Martin Tesli;Thorgeir E. Thorgeirsson;Jackson G. Thorp;Claudio Toma;Leonardo Tondo;Paul A. Tooney;Shih-Jen Tsai;Evangelia Eirini Tsermpini;Marquis P. Vawter;Helmut Vedder;Annabel Vreeker;James T. R. Walters;Bendik S. Winsvold;Stephanie H. Witt;Hong-Hee Won;Robert Ye;Allan H. Young;Peter P. Zandi;Lea Zillich;Rolf Adolfsson;Martin Alda;Lars Alfredsson;Lena Backlund;Bernhard T. Baune;Frank Bellivier;Susanne Bengesser;Wade H. Berrettini;Joanna M. Biernacka;Michael Boehnke;Anders D. Børglum;Gerome Breen;Vaughan J. Carr;Stanley Catts;Sven Cichon;Aiden Corvin;Nicholas Craddock;Udo Dannlowski;Dimitris Dikeos;Bruno Etain;Panagiotis Ferentinos;Mark Frye;Janice M. Fullerton;Micha Gawlik;Elliot S. Gershon;Fernando S. Goes;Melissa J. Green;Maria Grigoroiu-Serbanescu;Joanna Hauser;Frans A. Henskens;Jens Hjerling-Leffler;David M. Hougaard;Kristian Hveem;Nakao Iwata;Ian Jones;Lisa A. Jones;René S. Kahn;John R. Kelsoe;Tilo Kircher;George Kirov;Po-Hsiu Kuo;Mikael Landén;Marion Leboyer;Qingqin S. Li;Jolanta Lissowska;Christine Lochner;Carmel Loughland;Jurjen J. Luykx;Nicholas G. Martin;Carol A. Mathews;Fermin Mayoral;Susan L. McElroy;Andrew M. McIntosh;Francis J. McMahon;Sarah E. Medland;Ingrid Melle;Lili Milani;Philip B. Mitchell;Gunnar Morken;Ole Mors;Preben Bo Mortensen;Bertram Müller-Myhsok;Richard M. Myers;Woojae Myung;Benjamin M. Neale;Caroline M. Nievergelt;Merete Nordentoft;Markus M. Nöthen;John I. Nurnberger;Michael C. O’Donovan;Ketil J. Oedegaard;Tomas Olsson;Michael J. Owen;Sara A. Paciga;Christos Pantelis;Carlos N. Pato;Michele T. Pato;George P. Patrinos;Joanna M. Pawlak;Josep Antoni Ramos-Quiroga;Andreas Reif;Eva Z. Reininghaus;Marta Ribasés;Marcella Rietschel;Stephan Ripke;Guy A. Rouleau;Panos Roussos;Takeo Saito;Ulrich Schall;Martin Schalling;Peter R. Schofield;Thomas G. Schulze;Laura J. Scott;Rodney J. Scott;Alessandro Serretti;Jordan W. Smoller;Alessio Squassina;Eli A. Stahl;Hreinn Stefansson;Kari Stefansson;Eystein Stordal;Fabian Streit;Patrick F. Sullivan;Gustavo Turecki;Arne E. Vaaler;Eduard Vieta;John B. Vincent;Irwin D. Waldman;Cynthia S. Weickert;Thomas W. Weickert;Thomas Werge;David C. Whiteman;John-Anker Zwart;Howard J. Edenberg;Andrew McQuillin;Andreas J. Forstner;Niamh Mullins;Arianna Di Florio;Roel A. Ophoff;Ole A. Andreassen - 通讯作者:
Ole A. Andreassen
Clinical Challenges and Opportunities of Bipolar Disorder Genomics
- DOI:
10.1016/j.biopsych.2021.02.175 - 发表时间:
2021-05-01 - 期刊:
- 影响因子:
- 作者:
Arianna Di Florio;Kath Gordon-Smith;Lisa Jones;Nick Craddock;Ian Jones - 通讯作者:
Ian Jones
TU25. POLYGENIC PREDICTION OF LONGITUDINAL COURSE IN BIPOLAR DISORDER
- DOI:
10.1016/j.euroneuro.2021.08.028 - 发表时间:
2021-10-01 - 期刊:
- 影响因子:
- 作者:
Amedeo Primerano;Katherine Gordon-Smith;Lisa Jones;Valentina Escott-Price;Nick Craddock;Ian Jones;Arianna Di Florio - 通讯作者:
Arianna Di Florio
CLINICAL RELEVANCE OF GENOTYPE-PHENOTYPE ANALYSES WITHIN BIPOLAR DISORDER AND ACROSS THE MOOD AND PSYCHOSIS SPECTRUM
- DOI:
10.1016/j.euroneuro.2021.07.056 - 发表时间:
2021-10-01 - 期刊:
- 影响因子:
- 作者:
Arianna Di Florio;Amedeo Primerano;Charlotte Dennison;Alexander Richards;Lisa Jones;Katherine Gordon-Smith;Michael Owen;Ian Jones;Nick Craddock;Michael O'Donovan;Sophie Legge;James Walters - 通讯作者:
James Walters
Arianna Di Florio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
基于影像代谢重塑可视化的延胡索酸水合酶缺陷型肾癌危险性分层模型的研究
- 批准号:82371912
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
面向人工智能生成内容的风险识别与治理策略研究
- 批准号:72304290
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验:The ASCVD Risk Intervention Trial
- 批准号:81973152
- 批准年份:2019
- 资助金额:54.0 万元
- 项目类别:面上项目
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
- 批准号:71903144
- 批准年份:2019
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
RISK通路在胃泌素介导的心脏缺血再灌注损伤保护中的作用研究
- 批准号:81800239
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
异氟烷基于TLR4/RISK/NF-κB调控糖尿病缺血性脑卒中后NLRP3炎症小体形成的机制研究
- 批准号:81771232
- 批准年份:2017
- 资助金额:54.0 万元
- 项目类别:面上项目
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
- 批准号:81260024
- 批准年份:2012
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
基于VaR的水资源短缺风险综合模型体系与应用
- 批准号:51279006
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
黄淮海平原典型区域土壤盐渍化演变机制与发生风险防控对策研究
- 批准号:41171178
- 批准年份:2011
- 资助金额:65.0 万元
- 项目类别:面上项目
相似海外基金
Mental Health and Occupational Functioning in Nurses: An investigation of anxiety sensitivity and factors affecting future use of an mHealth intervention
护士的心理健康和职业功能:焦虑敏感性和影响未来使用移动健康干预措施的因素的调查
- 批准号:
10826673 - 财政年份:2024
- 资助金额:
$ 55.39万 - 项目类别:
Parent-adolescent informant discrepancies: Predicting suicide risk and treatment outcomes
父母与青少年信息差异:预测自杀风险和治疗结果
- 批准号:
10751263 - 财政年份:2024
- 资助金额:
$ 55.39万 - 项目类别:
Leveraging COVID-19 to modernize depression care for VA primary care populations
利用 COVID-19 实现 VA 初级保健人群的抑郁症护理现代化
- 批准号:
10636681 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
Anxiety in Youth with Autism Spectrum Disorder
自闭症谱系障碍青少年的焦虑
- 批准号:
10784337 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
Methylphenidate for the treatment of epilepsy-related cognitive deficits: a randomized, double-blind, placebo-controlled trial
哌醋甲酯治疗癫痫相关认知缺陷:一项随机、双盲、安慰剂对照试验
- 批准号:
10589709 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
A neurobiological investigation of cannabis use and misuse in Veterans
退伍军人大麻使用和滥用的神经生物学调查
- 批准号:
10588526 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC
将接受阿片类药物使用障碍治疗且吸烟的个体转至 SREC
- 批准号:
10661301 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
PTSD and Autoimmune Disease: Towards Causal Effects, Risk Factors, and Mitigators
创伤后应激障碍 (PTSD) 和自身免疫性疾病:因果效应、危险因素和缓解措施
- 批准号:
10696671 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:
Computational Strategies to Tailor Existing Interventions for First Major Depressive Episodes to Inform and Test Personalized Interventions
针对首次严重抑郁发作定制现有干预措施的计算策略,以告知和测试个性化干预措施
- 批准号:
10650695 - 财政年份:2023
- 资助金额:
$ 55.39万 - 项目类别:














{{item.name}}会员




